Efficacy and safety of the dual SGLT1 and 2 inhibitor sotagliflozin in combination with a mineralocorticoid receptor antagonist in patients hospitalized for worsening heart failure

被引：0
|
作者：
Pitt, B. [1 ]
Bhatt, D. L. [2 ]
Szarek, M. [3 ]
Davies, M. [4 ]
Banks, P. [4 ]
Steg, P. G. [5 ]
机构：
[1] Univ Michigan, Ann Arbor, MI USA
[2] Icahn Sch Med Mt Sinai, New York, NY USA
[3] Univ Colorado, Sch Med, Aurora, CO USA
[4] Lexicon Pharmaceut Inc, The Woodlands, TX USA
[5] Univ Paris Diderot, Bichat Hosp, INSERM, FACT French Alliance Cardiovasc T,UMR1148, Paris, France
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2023年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：192 / 193
页数：2
相关论文
共 50 条
  • [31] Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, reduces glucose variability in type 1 diabetes mellitus in a randomised, placebo-controlled, double-blind study
    Strumph, P. S.
    Sands, A. T.
    Rosenstock, J.
    Lapuerta, P.
    Bode, B. W.
    Garg, S. K.
    Buse, J. B.
    Banks, P.
    Heptulla, R.
    Rendell, M.
    Cefalu, W.
    Zambrowicz, B.
    DIABETOLOGIA, 2015, 58 : S368 - S368
  • [32] Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, improves glycaemic control in type 1 diabetes mellitus in a randomised, placebo-controlled, double-blind study
    Cefalu, W.
    Sands, A. T.
    Rosenstock, J.
    Lapuerta, P.
    Bode, B. W.
    Garg, S. K.
    Buse, J. B.
    Banks, P.
    Heptulla, R.
    Rendell, M.
    Zambrowicz, B.
    Strumph, P. S.
    DIABETOLOGIA, 2015, 58 : S92 - S92
  • [33] Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, Reduces Late but Not Early Postprandial Glucose Absorption in T1DM: Potential Implications for Recovery from Hypoglycemia
    Garg, Satish K.
    Bode, Bruce W.
    Buse, John B.
    Cefalu, William T.
    Heptulla, Rubina A.
    Rendell, Marc
    Rosenstock, Julio
    Banks, Phillip L.
    Lapuerta, Pablo
    Sands, Arthur T.
    Zambrowicz, Brian P.
    Strumph, Paul S.
    DIABETES, 2016, 65 : A281 - A281
  • [34] The combination therapy of mineral corticoid receptor antagonists and vasopressin receptor antagonist is useful for hospitalized heart failure patients
    Nishihata, Y.
    Nishi, Y.
    Yamazoe, M.
    Mizuno, A.
    Niwa, K.
    EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 : 85 - 85
  • [35] The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes
    He, Yan-Ling
    Haynes, William
    Meyers, Charles D.
    Amer, Ahmed
    Zhang, Yiming
    Mahling, Ping
    Mendonza, Anisha E.
    Ma, Shenglin
    Chutkow, William
    Bachman, Eric
    DIABETES OBESITY & METABOLISM, 2019, 21 (06): : 1311 - 1321
  • [36] A 12-Week Dose-Ranging Study of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes (inTandem4)
    Baker, Claire
    Wason, Suman
    Banks, Phillip
    Sawhney, Sangeeta
    Strumph, Paul
    DIABETES, 2017, 66 : A18 - A19
  • [37] Efficacy and Safety of SGLT-2 Inhibitors in Heart Failure Patients with Diabetes Mellitus
    Kubota, Yoshiaki
    A, K.
    Y, A.
    I, Y.
    M, K.
    T, Y.
    Y, M.
    T, Y.
    S, W.
    JOURNAL OF CARDIAC FAILURE, 2015, 21 (10) : S202 - S202
  • [38] A 12-week dose-ranging study of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes (inTandem4)
    Baker, C.
    Wason, S.
    Banks, P.
    Sawhney, S.
    Strumph, P.
    DIABETOLOGIA, 2017, 60 : S409 - S409
  • [39] The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
    Voors, Adriaan A.
    Angermann, Christiane E.
    Teerlink, John R.
    Collins, Sean P.
    Kosiborod, Mikhail
    Biegus, Jan
    Ferreira, Joao Pedro
    Nassif, Michael E.
    Psotka, Mitchell A.
    Tromp, Jasper
    Borleffs, C. Jan Willem
    Ma, Changsheng
    Comin-Colet, Joseph
    Fu, Michael
    Janssens, Stefan P.
    Kiss, Robert G.
    Mentz, Robert J.
    Sakata, Yasushi
    Schirmer, Henrik
    Schou, Morten
    Schulze, P. Christian
    Spinarova, Lenka
    Volterrani, Maurizio
    Wranicz, Jerzy K.
    Zeymer, Uwe
    Zieroth, Shelley
    Brueckmann, Martina
    Blatchford, Jonathan P.
    Salsali, Afshin
    Ponikowski, Piotr
    NATURE MEDICINE, 2022, 28 (03) : 568 - +
  • [40] Incidence and potential predictors of SGLT2 inhibitor initiation in acutely hospitalized patients with heart failure
    Lanier, Cameron
    Brumit, Jessica C.
    Tharp, Jennifer
    Crawford, Jacquelyn
    White, Kathleen M.
    Wilson, Vera
    Covert, Kelly
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2025,
12345